About LimmaTech Biologics
LimmaTech Biologics is a Healthcare company based in Schlieren (Switzerland) founded in 2015 by Paul Wolfrom, and was acquired by Lilly in May 2026. Bioconjugate vaccines are developed using glycoengineering and protein glycosylation techniques. LimmaTech Biologics has raised $40 million across 4 funding rounds from investors including Lilly, CARB-X and AXA Investment Managers. LimmaTech Biologics offers products and services including Proprietary Vaccine Platform and Additional Technologies. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is LimmaTech Biologics AG.
Company details
LimmaTech Biologics was founded in 2015 in Schlieren, Switzerland, as a spin-off from GlycoVaxyn after its acquisition by GSK. Bioconjugate vaccines are developed and manufactured in the biopharmaceutical sector using proprietary glycoengineering and protein glycosylation methods. The platform is applied exclusively to vaccines for GSK, with additional applications of the technology explored in other areas.
- Headquarters Schlieren, Switzerland
- Founders Paul Wolfrom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lmtbio.com
- Social LinkedIn
- Acquired by Lilly (May 2026)
- Legal Name Limmatech Biologics Ag
Products & Services of LimmaTech Biologics
LimmaTech Biologics offers a comprehensive portfolio of products and services, including Proprietary Vaccine Platform and Additional Technologies.
Platform for developing self-adjuvanting vaccines against resistant pathogens.
Approaches for disease-specific vaccines targeting microbial infections.
Funding Insights of LimmaTech Biologics
LimmaTech Biologics has successfully raised a total of $40M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2.2 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 4
- Last Round Grant — $2.2M
- Investors Count 6
All 4 funding rounds of LimmaTech Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $2.2M | Grant | – | – | |
| Feb 2024 | $3M | Series A | – | Tenmile | – |
| Oct 2023 | $37M | Series A | – | Adjuvant Capital, AXA Investment Managers | – |
| Oct 2023 | Seed | – | – |
7 investors in total: 7 institutional.
Investors in LimmaTech Biologics
LimmaTech Biologics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, CARB-X and AXA Investment Managers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health technology investments are made by Tenmile in Australia. | tenmile.com | Perth, Australia | ||
Venture capital is deployed for global health technology innovations. | adjuvantcapital.com | New York City, USA | ||
Diversified alternative assets are managed through investment strategies. | 1994 | axa-im.com | Puteaux, France | |
Venture capital fund focused on solutions targeting resistant micro-organisms | repair-impact-fund.com | Hellerup, Denmark | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for LimmaTech Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of LimmaTech Biologics
5 people are tracked at LimmaTech Biologics (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Paul Wolfrom | Co-Founder & CFO | Leadership |
Patricia Martin Killias | Chief Operating Officer | Leadership |
Franz-Werner Haas | Chief Executive Officer | Leadership |
Angelika Breitfelder | Office-manager | Team |
Michael Kowarik | CSO | Team |
Complete people profiles for LimmaTech Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of LimmaTech Biologics
4 dated milestones of LimmaTech Biologics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded LimmaTech Biologics is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $2.2M.
- Exit Acquired by Lilly.
Web traffic of LimmaTech Biologics
The website of LimmaTech Biologics (lmtbio.com) receives about 4.8K visits a month.
- Monthly visits4.8K
▲ 11.2% vs previous month
Websites whose visitors overlap most with LimmaTech Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| schlattergroup.com | 100% | 6.2K | #2,890,041 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Limmatech Biologics
Complete news archive for LimmaTech Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LimmaTech Biologics
LimmaTech Biologics was founded in 2015 and raised its 1st funding round 8 years after it was founded.
LimmaTech Biologics is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
LimmaTech Biologics is a funded company, having raised a total of $40M across 4 funding rounds to date.
LimmaTech Biologics was founded in 2015 in Schlieren, Switzerland, as a spin-off from GlycoVaxyn after its acquisition by GSK. Bioconjugate vaccines are developed and manufactured in the biopharmaceutical sector using proprietary glycoengineering and protein glycosylation methods. The platform is applied exclusively to vaccines for GSK, with additional applications of the technology explored in other areas.
LimmaTech Biologics offers Proprietary Vaccine Platform and Additional Technologies.
LimmaTech Biologics has 7 investors. Key investors include Lilly, CARB-X, AXA Investment Managers, Tenmile, and Adjuvant Capital.
LimmaTech Biologics operates through Limmatech Biologics Ag.
Yes. LimmaTech Biologics was acquired by Lilly in May 2026.